SEARCH

SEARCH BY CITATION

References

  • 1
    Raghupathy R: Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. Semin Immunol 2001; 13:219227.
  • 2
    Vince GS, Johnson PM: Materno-fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Hum Reprod 1995; 10:107113.
  • 3
    Abbas AK, Lichtman AH, Pober JS: Effector Mechanisms of Humoral Immunity. Cellular and Molecular Immunology. Philadelphia, PA, W.B. Saunders Company, 2000.
  • 4
    Schmidt BZ, Colten HR: Complement: a critical test of its biological importance. Immunol Rev 2000; 178:166176.
  • 5
    Walport MJ: Complement. First of two parts. N Engl J Med. 2001; 344:10581066
  • 6
    Walport MJ: Complement. Second of two parts. N Engl J Med. 2001; 344:11401144
  • 7
    Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, Hechtman HB, Carroll MC: Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996; 183:23432348.
  • 8
    Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM: Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003; 170:15171523.
  • 9
    Hart ML, Walsh MC, Stahl GL: Initiation of complement activation following oxidative stress. In vitro and in vivo observations. Mol Immunol 2004; 41:165171.
  • 10
    Fearon DT: Seeking wisdom in innate immunity. Nature 1997; 388:323324.
  • 11
    Hugli TE: Structure and function of C3a anaphylatoxin. Curr Top Microbiol Immunol 1990; 153:181208.
  • 12
    Brown EJ: Complement receptors and phagocytosis. Curr Opin Immunol 1991; 3:7682.
  • 13
    Holers VM: Complement. In Principles and Practices of Clinical Immunology RRich (ed). St Louis, MO, Mosby, 2001, 21.121.8.
  • 14
    Wetsel RA: Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 1995; 7:4853.
  • 15
    Shin ML, Rus HG, Nicolescu FI: Membrane attack by complement: assembly and biology of terminal complement complexes. Biomembranes 1996; 4:123149.
  • 16
    Morgan BP, Meri S: Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15:369396.
  • 17
    Devine DV: The effects of complement activation on platelets. Curr Top Microbiol Immunol 1992; 178:101113.
  • 18
    Morgan BP: Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol 1992; 178:115140.
  • 19
    Benzaquen LR, Nicholson-Weller A, Halperin JA: Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179:985992.
  • 20
    Hattori R, Hamilton KK, McEver RP, Sims PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264:90539060.
  • 21
    Qin X, Krumrei N, Grubissich L, Dobarro M, Aktas H, Perez G, Halperin JA: Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 2003; 18:217227.
  • 22
    Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G: Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362:15421547.
  • 23
    Holmes CH, Simpson KL: Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship. Balliere’s Clin Obstet Gynecol 1992; 6:42394459.
  • 24
    Rooney IA, Oglesby TJ, Atkinson JP: Complement in human reproduction. Activation and control. Immunol Res 1993; 12:276294.
  • 25
    Weetman AP: The immunology of pregnancy. Thyroid 1999; 9:643646.
  • 26
    Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP: Control of the complement system. Adv Immunol 1996; 61:201283.
  • 27
    Holers VM, Kinoshita T, Molina H: The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today 1992; 13:231236.
  • 28
    Cunningham DS, Tichenor JR: Deacy-accelerating factor protects human trophoblast from complement-mediated attack. Clin Immunol Immunopathol 1995; 74:156161.
  • 29
    Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C: Susceptibility of human trophoblast to killing by human complement and the role of complement regulatory proteins. J Immunol 1993; 151:15621570.
  • 30
    Kim YU, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, Holers VM: Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 1995; 181:151159.
  • 31
    Xu C, Mao D, Holers VM, Palanca B, Cheng A, Molina H: A critical role for the murine complement regulator Crry in fetomaternal tolerance. Science 2000; 287:498501.
  • 32
    Micheloud D, Sarmiento E, Teijeiro R, Jensen J, Rodríguez Molina JJ, Fernández-Cruz E, Carbone J: Hypocomplementemia in the absence of autoantibodies in women with recurrent pregnancy loss. Allergol Immunopathol (Madr) 2007; 35:9094.
  • 33
    Richani K, Romero R, Soto E, Espinoza J, Nien JK, Chaiworapongsa T, Refuerzo J, Blackwell S, Edwin SS, Santolaya-Forgas J, Mazor M: Unexplained intrauterine fetal death is accompanied by activation of complement. J Perinat Med 2005; 33:296305.
  • 34
    Shamonki JM, Salmon JE, Hyjek E, Baergen RN: Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196:167.
  • 35
    Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE: Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 95:211220.
  • 36
    Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE: Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2004; 112:16441654.
  • 37
    Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G: Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110:24232431.
  • 38
    Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, Taylor SM: Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. Med Chem 1999; 42:19651974.
  • 39
    Derksen RH, Khamashta MA, Branch DW: Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50:10281039.
  • 40
    Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119:64S94S.
  • 41
    Menon V, Berkowitz SD, Antman EM, Fuchs RM, Hochman JS: New heparin dosing recommendations for patients with acute coronary syndromes. Am J Med 2001; 110:641650.
  • 42
    Girardi G, Redecha P, Salmon JE: Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:12221226.
  • 43
    Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF: Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981; 67:223228.
  • 44
    Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegård KT, Köhl J, Lambris JD: Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100:18691877.
  • 45
    Stone S, Pijnenborg R, Vercruysse L, Poston R, Khamashta MA, Huntb BJ, Poston L: The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006; 27:457467.
  • 46
    Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417430.
  • 47
    Kirchhofer D, Moran P, Bullens S, Peale F, Bunting S: A monoclonal antibody that inhibits mouse tissue factor function. J Thromb Haemost 2005; 3:10981099.
  • 48
    Pawlinski R, Pedersen B, Erlich J, Mackman N: Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost 2004; 92:444450.
  • 49
    Clark DA, Chaouat G, Arck PC, Mittruecker HW, Levy GA: Cytokine-dependent abortion in CBA × DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase]. J Immunol 1998; 160:545549.
  • 50
    Blois S, Tometten M, Kandil J, Hagen E, Klapp BF, Margni RA, Arck PC: Intercellular adhesion molecule-1/LFA-1 cross talk is a proximate mediator capable of disrupting immune integration and tolerance mechanism at the feto-maternal interface in murine pregnancies. J Immunol 2005; 174:18201829.
  • 51
    Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203:21652175.
  • 52
    Lam C, Lim KH, Karumanchi SA: Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46:10771085.
  • 53
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649658.